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Abstract
A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney 
Diseases to focus on research gaps and opportunities on drug development for pancreatitis. This 
conference was held on July 25th, 2018 and structured into three working groups (WG): Acute 
Pancreatitis (AP) WG, Recurrent Acute Pancreatitis WG and Chronic Pancreatitis WG. This paper 
reports the outcome of the work accomplished by the AP WG to provide the natural history, 
epidemiology, and current management of AP; inform about the role of preclinical models in 
therapy selection; and discuss clinical trial designs with clinical and patient reported outcomes to 
test new therapies.
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INTRODUCTION
Acute Pancreatitis (AP) is defined by meeting two out of the three criteria: abdominal pain 
and symptoms suggestive of pancreatitis, lipase and/or amylase three times the upper limit 
of normal, and image findings of AP.1,2 Acute pancreatitis is a leading cause of emergency 
department visits and gastrointestinal admissions in the United States (U.S.).3–5 
Hospitalizations costs are well above $2 billion annually.6 This constitutes a health and 
economic burden with increased hospitalizations, medications, lost work and school time for 
the patients and caregivers. There has been increasing trends in incidence of AP in adults 
with 30–100/100,000 (250,000 cases per year in the US alone,7,8 and in children up to 
13/100,000/year.9–13 In most patients, pancreatic damage ultimately resolves, but in severe 
cases unremitting persistent systemic inflammatory response (SIRS) leads to multiple organ 
(especially lung) failure, a major cause of mortality among patients with AP. In adult cases, 
AP has a mortality rate of up to 6%,14 but as many as 50% of patients with severe disease 
associated with persistent multi-organ dysfunction have a risk of death.14–16 The majority of 
cases in children are mild, with a subset that progress to severe acute pancreatitis (SAP) with 
increased risk of complications, prolonged length of stay (LOS) and significant morbidity.
17–19 Severe acute pancreatitis in children represents 15–30% of all cases depending on the 
definition used.20–23 With the rise in AP incidence, and its high morbidity rates,17–19 
significant advances in prevention and treatment are urgent. However, we strongly believe 
that the incidence rate is still much higher than currently diagnosed. A multinational 
prospective clinical trial aiming to answer the real incidence rate of AP in children is in 
process (Pain in early phase of pediatric pancreatitis [PINEAPPLE] trial). 24
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Pancreatitis has been associated with gallstones, alcohol abuse, hypertriglyceridemia, and 
genetic factors. Hallmark responses of AP include hyperamylasemia, inappropriate 
activation of digestive enzymes (e.g., conversion of trypsinogen to trypsin), accumulation of 
large vacuoles in acinar cells, induction of proinflammatory signals (e.g., the key 
transcription factor nuclear factor-κB [NF-κB]) resulting in inflammatory cell infiltration in 
the pancreas, a systemic inflammatory response and acinar cell death through apoptosis and 
necrosis.25,26 The pathogenesis of AP it is not fully understood, but evidence from basic 
science studies indicates critical roles for pathologic calcium signals, NF-κB and zymogen 
activation.27 Other observations in experimental and human AP have shown the formation of 
cytoplasmic vacuoles in acinar cells that represent disordered autophagy. Activation of 
trypsinogen to trypsin occurs then possibly through cathepsin B in these abnormal 
autophagic vacuoles.28 Further, the mechanisms leading to trypsinogen activation as well as 
how trypsin causes AP are largely unknown. Recent insights into the pathogenic mechanism 
of pancreatitis provided novel information on role of acinar cell organelle disorders in AP.
26,29
Despite advances in understanding of the pathobiology of AP,26 there is currently no 
pharmacologic therapy that has demonstrated efficacy in altering the natural history of the 
disease course. As a result, the mainstay of treatment continues to be entirely based on 
supportive care and management of complications.
A barrier to drug development in AP is the reduction in investment on novel drug research 
and development (R&D) that is part of a larger overall trend. Research investment in novel 
drug R&D decreased from $21 billion (2004–2008) to $17 billion (2009–2013). 
Unfortunately, the biggest decrease was in gastrointestinal (GI) diseases (62% from $828 
million to $311 million). Furthermore, the relative research activity in pancreatitis dropped 
from 25.7% to 10.7% in the last 50 years compared to other GI inflammatory disorders.30
The objectives of the AP working groups were to address four main domains pertinent to 
development of drug therapy in AP: (1) Natural history, epidemiology and current 
management, (2) Preclinical models, and animal models of AP, (3) Potential therapeutic 
targets, and (4) Risk stratification and patient selection.
NATURAL HISTORY AND CURRENT MANAGEMENT OF ACUTE PANCREATITIS
According to the revised Atlanta classification, around 2/3 of AP is categorized as mild, 20–
30% moderate, and 5–10% as severe. The overall mortality is up to 6%.14 As many as 50% 
of patients with severe disease have a risk of mortality.14–16 In children, the majority of 
patients experience mild disease, with 15–34% developing SAP with attendant morbidity 
and mortality.19,22,31 A paucity of prospective studies is an obstacle to understanding the 
natural history and identification of risk stratified therapies in pediatric AP.
Biliary and alcoholic pancreatitis are the two most common causes of AP in adults,32,33 
while pediatric cases are associated with a variety of etiologies that encompass biliary, 
metabolic/systemic factors, hereditary and anatomic anomalies.12,34–36
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In terms of risk factors in adult SAP, there have been several risk factors studied including 
aging, comorbidities, hypertriglyceridemia, elevated Body Mass Index (BMI), and pre-
existing diabetes.37 A number of scoring systems and simple laboratory markers have been 
developed with the aim of predicting prognosis during the early phase of AP. 
Hemoconcentration, elevated blood urea nitrogen (BUN), elevated C-reactive protein (CRP), 
an elevated Ranson’s score, APACHE (Acute Physiology And Chronic Health Evaluation) II 
score and SIRS have been associated with severe AP. However, the accuracy of both 
individual or combination of scoring systems such as BISAP (Bedside Index of Severity in 
Acute Pancreatitis ), or the HAPS (Harmless Acute Pancreatitis Score) needs to be 
improved.38–40 To date, there is no validated pediatric severity scoring system.41,42 The 
applicability of various clinical scoring systems for intervention trials in AP is described 
below in the discussion on risk-stratification.
In respect to current management, early (first 24h) adequate intravenous fluid resuscitation, 
enteral feeding in predicted severe and severe AP, early endoscopic retrograde 
cholangiopancreatography (ERCP) in biliary AP with concomitant biliary obstruction or 
cholangitis, and delaying surgical interventions for infectious complications have been 
shown to be of high importance. The most common local complication is peripancreatic 
fluid collections, whereas the most common distant organ failure is lung injury. Importantly, 
centralized care improves, whereas deviation from the recommendations of the International 
Association of Pancreatology/American Pancreatic Association evidence-based guidelines 
was found to worsen, the outcome of AP.43
PRECLINICAL/ANIMAL MODELS IN ACUTE PANCREATITIS RESEARCH
The pathophysiologic mechanisms of AP are not completely known.27,44 Mechanistic 
studies have been largely performed in rodent tissues as human tissue is difficult to obtain 
during the disease process. Recent studies in pancreatic parenchymal cells have revealed that 
pathobiologic pathways in rodent and human tissue are probably the same. In the context of 
drug development, it is important to determine the suitability of various experimental animal 
models for testing of potential novel therapeutic agents.
Over the past several decades, different species have been used in experimental studies,45–51 
but currently mice are preferred because of the availability of strains with specific genetic 
deletions, low cost housing and other resources related to this species.52–55 In the animal 
models, the disease is induced experimentally by common duct ligation, hyper-stimulation 
using cholecystokinin analogs, retrograde injection of bile acids or other chemicals or 
dietary modifications.56 The end result of such insults is acute pancreatic inflammation and 
necrosis of varying severity with symptoms resembling clinical disease. These models have 
been used extensively by investigators to understand the mechanism of the disease as well as 
pre-clinical models for testing of therapeutic agents. Methods of induction of disease may or 
may not have an etiological equivalent for human disease and this limitation has often been 
used to criticize the relevance of a model to the human disease.57 Using these experimental 
animal models, the ‘Auto digestion Hypothesis’ and role of ‘Gall stone induced blockage of 
pancreatic flow or influx of bile in pancreatic duct’ in biliary pancreatitis have been 
rigorously tested and published.58–61 Based upon these studies, consensus exists regarding 
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the early activation of digestive enzymes in the pancreas in response to insult and pancreatic 
acinar cells being the primary site of initiation of injury in AP.62 Whether the blockage of 
pancreatic flow itself is sufficient in inducing AP or the influx of bile is required to trigger 
the disease was answered by the development of an animal model with anatomical similarity 
to the human pancreatic biliary ductal system.61,63
Although these animal-based experimental models have helped us to understand the steps 
involved in the initiation and progression of the disease, there are several limitations. Human 
patients comprise a diverse population with different genetic backgrounds and different 
epigenetics and dietary preferences, which, on their own or in combination, can contribute to 
susceptibility, severity and progression of the disease. In animal models, full recovery is 
mostly observed although in patients, the disease might follow a complicated course with 
extended hospitalization. The distribution of bile acid surface receptors is different in rodent 
acinar and human cells, thereby making the applicability of the conclusions from rodent 
models to human disease difficult. Overall, experimental animal models are important for 
understanding the disease mechanism but due considerations should be given to the 
dissimilarities in rodent and human pancreatitis when extrapolating these findings in animals 
for developing strategies to treat human AP.
POTENTIAL MOLECULAR TARGETS IN AP
The current paradigm is that AP originates in injured acinar cells. Its manifestations 
(responses) are inappropriate, intra-acinar activation of digestive enzymes, in particular 
conversion of trypsinogen into active trypsin, dysregulation and inhibition of secretion, and 
activation of inflammatory transcription factors, followed by the inflammatory cell 
infiltration and necrosis, which are the major determinants of disease severity.4,25,26 
Experimental studies strongly indicate that the inflammatory, especially neutrophilic, 
response in AP is non-resolving/un(der)controlled, and its down-regulation could have 
beneficial effects. To date, our knowledge of the inflammatory response in pancreatitis has 
not translated into effective therapies. One cause of non-resolving inflammation in AP could 
be unremitting acinar cell injury, which perpetuates the inflammatory response—a vicious 
cycle of parenchymal necrosis and immune cell infiltration.
Considerable progress has been achieved during the last decade in elucidating the nature of 
acinar cell injury leading to AP. Several critical cellular processes that become disordered in 
acinar cells have been elucidated and shown to drive (or even initiate) AP. In particular, 
pancreatitis causes disordering of autophagy, the principal catabolic cellular pathway for 
degradation and recycling of unneeded or dysfunctional cytoplasmic organelles.29,64,65 This 
results in accumulation in acinar cells of large vacuoles with poorly degraded cargo, a long-
noted feature of pancreatitis. Impaired autophagy is a common feature of all experimental 
AP models and is prominent in human disease.29,64,65 Recent studies in genetic models66–69 
provide mechanistic insights into the role of autophagy in pancreas: autophagy blockade or 
impairment triggers spontaneous pancreatitis in 4 different knockout mouse strains. These 
findings indicate that enhancing autophagic efficiency could be a promising approach for AP 
treatment. Impaired/inefficient autophagy is a common feature of various neurodegenerative 
diseases, and pharmacologic agents are being developed to normalize autophagy in these 
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diseases. These approaches should be tested for AP in pre-clinical studies. For example, it 
was found that the disaccharide trehalose, known to enhance autophagy and improve the 
outcome in neurodegenerative diseases, greatly ameliorates pathologic responses in 2 mouse 
models of AP.70
Mitochondrial dysfunction is another key organelle disorder both in acinar and ductal cells 
found in AP.29,70–76 Pancreatitis causes persistent opening of a non-selective channel in the 
mitochondrial membrane, called the permeability transition pore (MPTP), resulting in 
mitochondrial depolarization and fragmentation followed by drop in ATP level – features 
prominent in various experimental AP models and in human disease. The protein cyclophilin 
D is a key mediator of MPTP opening, and studies have shown that genetic or 
pharmacologic knockdown of cyclophilin D abolishes or greatly reduces both local 
(pancreatic) and systemic pathologic responses in multiple experimental models of AP.
29,70–72 These findings validate restoring mitochondrial function as a promising approach for 
AP treatment.70 In this regard, a UK-based company, is pursuing preclinical development of 
cyclophilin D inhibors for potential treatment for AP. In addition, a registered multicentre 
randomised double-blind clinical trial investigating the effects of high energy in the early 
phase of acute pancreatitis (High versus low energy administration in early phase of 
pancreatitis [GOULASH] trial) is currently ongoing.77
The physiologic digestive enzyme secretion from acinar cells is mediated by oscillatory 
increases of cytosolic Ca2+ triggered in response to neurotransmitters such as acetylcholine. 
The increases result from Ca2+ released from endoplasmic reticulum (ER) stores and are 
transient because the released Ca2+ is rapidly re-uptaken into the stores. In contrast, several 
AP triggers, such as bile salts, or acinar cells’ hyperstimulation with caerulein, cause 
massive and persistent Ca2+ release from ER stores resulting in their sustained Ca2+ 
depletion.78,79 In this state, the acinar cell attempts to refill ER stores by Ca2+ entry through 
the activation of the plasma membrane CRAC channel,78,79 resulting in sustained increase in 
cytosolic Ca2+. Sustained increase in cytosolic Ca2+ causes acinar cell damage through 
several pathways directly or through activating the Ca2+-dependent phosphatase calcineurin. 
For example, increase in cytosolic Ca2+ causes its uptake by mitochondria leading to 
mitochondrial Ca2+ overload, which in turn causes mitochondrial depolarization, decrease in 
ATP synthesis and, ultimately, necrosis.71,72 Calcineurin further exacerbates mitochondrial 
dysfunction by promoting mitochondrial fragmentation.80 In addition, Ca2+ directly and 
through calcineurin stimulates activation of the proinflammatory transcription factors NF-
κB and NF-AT.81 Recent reports demonstrate that approaches to inhibit the CRAC channel 
or prevent calcineurin activation both attenuate experimental pancreatitis, suggesting them as 
important targets for disease treatment.78–83 The importance of calcium toxicity has also 
been widely investigated in pancreatic ductal cells. Bile acids, fatty acids, ethanol and even 
the activated trypsin have been shown to trigger two phases toxic calcium elevation causing 
decreased fluid and bicarbonate secretion.84–86 Of note, one of a series of CRAC inhibitors 
(developed by a U.S.-based company) has reached a phase I clinical trial.87
Finally, pancreatic fluid and bicarbonate secretion seems to be protective against acute 
pancreatitis. Pancreatitis induced either aquaporin 1−/−, CFTR−/− or NHERF1−/− mice 
resulted more severe pancreatitis.88–90 On the other hand all pancreatitis inducing factors 
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were shown not only damaging to the acinar cells but decreasing fluid and bicarbonate 
secretion as well.60,90,91
Table 1, lists potential approaches for AP treatment, including normalizing autophagic and, 
mitochondrial functions, blocking Ca2+ influx through CRAC channels, and inhibiting Ca2+-
dependent phosphatase calcineurin.
RISK STRATIFICATION AND SUBJECT SELECTION
A patient is given a diagnosis of AP by meeting two out of three criteria: upper abdominal 
pain and symptoms suggestive of pancreatitis, serum lipase and/or amylase three times the 
upper limit of normal, and image findings of AP on cross-sectional imaging.1,2
Identification of Complication Risk—Both local (pancreatic or peri-pancreatic) 
complications as well as systemic complications (distant organ failure) may occur in the 
setting of AP. Consensus-based definitions for complications related to AP have been 
previously described and incorporated into classification systems for categorizing the 
severity of AP.1,92 The most widely recognized complications of AP are pancreatic necrosis 
and distant organ failure (respiratory failure, renal failure, and/or circulatory shock). Both 
the revised Atlanta criteria and determinants-based classification systems make a distinction 
according to the duration of organ failure with emphasis placed on persistent (>48 hours) 
organ failure as the most ominous complication defining SAP.
While the frequency of major complications related to AP is relatively low, the 
consequences of SAP can be life-threatening. As such, substantial effort has been devoted to 
developing strategies for early identification of patients at increased risk for complications 
related to AP. Numerous approaches to risk stratification have been developed that include 
clinical prediction scores, biochemical parameters as well as machine learning algorithms.38 
A comparison of nine scoring systems in two prospectively collected cohorts of patients 
hospitalized for AP did not demonstrate clear advantage in terms of accuracy for any 
specific approach to identify patients at increased risk for persistent organ failure.38 As a 
result, most clinical practice guidelines43 currently recommend use of a simplified 
assessment system such as the systemic inflammatory response syndrome (SIRS) score that 
comprises vital signs and laboratory parameters to assess the extent of systemic 
inflammation related to an AP episode. It should be noted that SIRS is not specific to AP. 
However, previous studies have demonstrated an association between the duration of SIRS 
(lasting>48 hours) with persistent organ failure as well as mortality in AP.1,43
Definition of Endpoints/Outcomes—Selection of study endpoints in AP should be 
determined based on the context of the proposed intervention. Traditional approaches for 
development of novel therapeutics in AP have focused on prevention of severe forms of 
illness. These studies incorporated initial risk-stratification to identify a higher-risk subgroup 
of patients for outcomes such as persistent organ failure or mortality.93 In these trials, organ 
failure is typically defined based on an established scoring system such as the Modified 
Marshall Score [Atlanta] and mortality is typically defined as in-hospital death.1
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Additional outcomes to be considered in AP might include amelioration of disease or 
expedited recovery. Length of stay has often been reported in studies of AP.94,95 However, 
LOS is problematic as an outcome parameter as it can be influenced by factors unrelated to 
the disease process and is a poor overall measure of disease activity. To address these 
limitations, a disease-specific activity measurement scale has recently been developed 
through a consensus-based process.96 This scale, the Pancreatitis Activity Scoring System or 
PASS comprises five domains: ability to tolerate oral intake, abdominal pain, opioid 
requirement, SIRS, and organ failure. Each of these components is given a weighted score 
with the total score represented as the sum of each individual category. The score is designed 
to be calculated based on 12-hour intervals to reflect dynamic changes in disease status. In a 
validation study using a prospective cohort of consecutively admitted patients (excluding 
hospital transfers) an elevated PASS at admission (>140) was shown to be associated with 
increased risk of moderate and severe pancreatitis while a discharge PASS >60 was 
associated with increased risk of early re-hospitalization.97
Critical Path Innovation Meeting: To explore the next steps in development of clinical 
outcome assessment (COA) tools in AP, a Critical Path Innovation Meeting was convened 
with members from the FDA Center for Drug Evaluation and Research on October 26, 2017. 
The intent of the meeting was to learn more about the FDA drug development tool (DDT) 
qualification process as well as discussion regarding additional considerations for further 
development of the PASS instrument as a COA in AP. The findings from the meeting are 
intended to be available in the public domain and a summary of the meeting is included as 
Supplemental Digital Content 1.
Performance Characteristics of Measures—In a previous systematic literature review 
of clinical trials in AP involving human subjects 61 studies were identified from 1996–
2014.98 The most common primary outcome was mortality (16%). Other common outcome 
parameters included organ failure (15%), pancreatic infections (13%), and SIRS (10%). 
Included in the review were nine studies that evaluated pharmacologic intervention in AP.98
Among these trials the Lexipifant study merits special consideration as the study design 
reflects most closely the established paradigm for testing early intervention in AP. In this 
phase III study, investigators in the United Kingdom conducted a large scale multi-center 
trial to evaluate the impact of early treatment (initiation of therapy within 72 hours of 
symptom onset) on disease course in patients with predicted severe AP.93 The primary 
outcome measure was incidence of complications (organ failure, necrotizing pancreatitis, or 
acute fluid collections). The study was powered based on an assumed reduction from a 40% 
complication rate in the placebo arm to 24% in the intervention arm. However, after 
completing the trial, the investigators noted that only 14% of enrolled study participants 
developed new-onset organ failure. In addition, assessment of local complications (necrosis, 
fluid complications) was complicated by the fact that cross-sectional imaging was performed 
in less than half of the study participants (45% in placebo group, 38% in the intervention 
arm).
As a case study, the Lexipifant trial highlights several of the challenges with studying the 
impact of widely accepted outcome parameters such as persistent organ failure or necrosis. 
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In the case of the former, organ failure is a rare outcome even among patients with predicted 
severe disease. In the case of necrosis, this is a radiographic finding that can be problematic 
with respect to ascertainment given not all subjects will typically undergo cross-sectional 
imaging during hospitalization.
Subject Selection for Drug Trials and Time of Treatment
A major challenge in designing clinical trials for testing new drug treatments in AP relates to 
participant selection as well as timing of intervention. Work from previous observational 
studies has shown that the precision with which a patient’s outcome can be predicted 
increases over time. However, delays in initiating therapy may limit the subsequent 
observable effect of an intervention. The following potential strategies address these 
limitations:
- Recruitment of all potentially eligible participants with established AP 
irrespective of disease severity. This trial design would be best suited for low-
cost interventions intended to ameliorate the overall disease course. Advantages 
of this approach would include rapid accrual and the ability to initiate 
intervention as early as possible as well as the ability to broadly generalize the 
study findings to the AP population at large. Disadvantages of this approach 
would include limited feasibility to assess for outcomes such as persistent organ 
failure or necrosis given the anticipated low incidence in the general AP 
population.
- Stratified randomization based on initial markers of disease severity. Ensuring 
equal distribution of participants at risk for severe illness is paramount in 
circumstances where the impact of an intervention may vary based on the extent 
of disease activity (effect modification). In these settings, stratified 
randomization based on markers of initial disease severity available at the time 
of enrollment will help to ensure balanced representation across the study arms. 
An adaptive study design with a priori criteria to evaluate for feasibility can help 
to target further enrollment criteria following planned interim analysis.
- Randomization following ‘run-in’ period. Newly developed drugs that can 
prevent or diminish complications related to SAP are of critical importance. 
However, such agents will likely bear increased cost related to the expense 
associated with drug development. As a result, these newer agents will most 
likely be used as second-line therapy in clinical practice reserved for those 
patients not responding to standard resuscitation protocols. A trial design that 
incorporates a run-in period can be used to reflect this reality as well as enrich 
the study population with patients most likely to experience severe forms of AP. 
In this study design, eligible patients are identified at the time of presentation to 
the hospital but randomization only occurs once they have undergone a period of 
initial fluid resuscitation to evaluate for ongoing eligibility.
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Logistical and Regulatory Issues in AP Related Drug Trials
A number of logistical and regulatory factors must be addressed in order to successfully 
conduct early intervention trials in AP. One challenge is that patients may present at various 
times in their disease course, which would make the initiation of therapy at an “early” stage 
difficult. The effect of timing with respect to onset of symptoms and initiation of therapy is 
an important consideration. Future trials should either incorporate the timing of symptom 
onset in their eligibility assessment criteria or at least carefully record this information for 
study participants in order to ascertain the optimal therapeutic window for future treatment.
Similar to other serious acute illnesses, caring for patients hospitalized for AP involves 
coordination among multiple disciplines including emergency medical teams, inpatient care 
services as well as potentially intensive care units or surgical teams. As a result, a successful 
trial requires the participation of multiple investigative teams comprising all providers that 
may be involved in the care of patients with AP.
Several key steps are needed to facilitate regulatory approval of new agents for treatment of 
acute pancreatitis. First is the development of disease-specific clinical endpoints to 
demonstrate efficacy of a new therapeutic intervention. An overview of the development of 
clinical outcome assessment as part of a drug development tool qualification program can be 
found at the FDA website: https://www.fda.gov/drugs/developmentapprovalprocess/
drugdevelopmenttoolsqualificationprogram.
Types of clinical outcome assessments include patient-, clinician-, or observer-reported 
outcomes as well as performance outcome measures. Of particular interest are patient 
reported outcomes (PROs), which have not been thoroughly evaluated in AP. In addition, 
long-term outcomes of AP merit further consideration. With the recent observations that 15–
30% of patients develop impaired glucose tolerance or diabetes within three years after a 
single episode of AP,99,100 it is important to follow patients for longer observation periods 
after treatment. Furthermore, recent studies have shown that the quality of life of patients 
remains impaired in the long term following an AP attack.101
RESEARCH GAPS AND OPPORTUNITIES
As the study of AP has evolved from natural history and epidemiology, to pathophysiology 
defined through preclinical models, to potential targets and clinical trial design, a number of 
factors remain, which are required to improve outcomes through the design of the next phase 
of human intervention studies.
• In terms of patient selection and defined outcomes, methods of defining 
pathobiologic pathways and severity are needed. This will allow a more 
“personalized” approach to therapy.
• Early prediction of SAP through novel blood and imaging biomarkers are 
needed.
• Patient reported outcomes (PRO) in AP are not well studied nor are PROs 
defined to measure the impact of AP on patients’ lives.
• PROs on pain, nutrition and quality of life should be developed for trials.
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• The most important endpoints of clinical trials are death and end- organ failure, 
but surrogate outcomes of severity such as CRP and procalcitonin need to be 
validated.
• The time points for follow up ranging from inpatient admission, to recovery, to 
post discharge are not well defined. Long-term follow up is lacking in most 
studies.
• Effect of disease beyond AP such recurrent acute pancreatitis, chronic 
pancreatitis, exocrine and endocrine insufficiency are poorly studied. These 
outcomes should be considered in study designs.
• Although most studies have focused on patients with predicted severe outcomes, 
including all AP patients at onset of disease may be the most appropriate 
approach to observe the prevention of progression to SAP, given the limitations 
of the prognostic scoring systems for predicting severity.
CONCLUSIONS
The workshop examined all aspects of AP from basic pathophysiology in preclinical models, 
and potential targets to clinical presentation, diagnosis, current management, severity 
predictive models to the defined outcomes. Studies that included adults as well as childhood 
AP were reviewed. Several gaps in the current understanding and management of AP were 
identified. Without addressing these gaps in designing clinical trials for treatment of AP, no 
further progress can be made. AP is the leading gastrointestinal disease for emergency 
department visits and hospitalizations, and therefore warrants further studies dedicated to 
target negative outcomes. The lack of animal models that mimic human disease remains a 
hindering factor to progress. Biomarkers to detect severity and disease pathways early on 
presentation are desperately needed to stratify patients with AP and allow targeted therapy 
designs. Future study designs should require input from regulatory agencies, focus on 
patient-related outcomes, develop well-defined and objective clinical outcomes to ensure 
progress in the management of AP that involves all stakeholders.
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Table 1.
Potential Molecular Targets for AP Therapy
Cellular Process to Target
Association With AP
Experimental Human Genetic Approaches Pharmacologic Approaches







Genetic approaches to block 
autophagy trigger 
spontaneous pancreatitis in 
4 genetic mouse models
Enhancing autophagy efficiency with 
trehalose prevented or alleviated 
pathologic responses in 2 mouse 
models in AP







Genetic approaches to 
restore mitochondrial 
function ameliorate AP in 
all models tested
Pharmacologic approaches to restore 
mitochondrial function greatly 
ameliorated AP severity in 4 models 
tested
Excessive Ca2+ Influx Shown in at least in 3 
experimental 
pancreatitis models
? ? Pharmacologic approaches to block 
CRAC channel alleviate AP in 3 
models tested
Calcineurin Activation Shown in a mouse 
model of post-ERCP 
pancreatitis
? Genetic approaches to block 
calcineurin alleviate 
inflammation
Pharmacologic approaches to inhibit 
calcineurin alleviate inflammation in a 
mouse model





Deletion of CFTR in at least 
3 animal models trigger 
spontaneous pancreatitis
VX-770 and VX-809 restore the 
expression cystic fibrosis 
transmembrane conductance regulator 
of CFTR
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